康安途海外就医 扫码咨询

海外医疗新方案

当前位置: 康安途海外医疗 > 关于我们 > 康安学术 >
康安途海外医疗

关于我们/康安学术

康安途海外医疗

据统计,全球约1.3-1.7亿人感染了丙型肝炎病毒(HCV)。慢性丙型肝炎病毒感染是导致肝脏相关死亡的主要原因之一,在许多国家它是主要的肝移植的原因。HCV抗病毒治疗的主要目标是根除病毒,直到几年前治疗策略都是聚乙二醇干扰素加利巴韦林(PEG/RBV)。然而,在基因1型和4型的患者中,PEG/RBV疗法的病毒反应率不超过50%,其他基因型的患者病毒反应率大概能达到80%。

2013年索非布韦(Sovaldi)及2014年哈瓦尼(Harvoni)的接连问世翻开了直接作用抗病毒药物(DAA)用于治疗HCV的新篇章:较短的疗程,更小的毒性(无需PEG/RBV),更高的SVR率(接近100%),泛基因型特性和良好的耐受性,使得它们几乎适用于所有的患者。近两年,FDA加速审批了一系列新的更有效的DAA药物。然而,应该指出的是,目前大多数公开的科学证据是基于专家意见,病例对照系列,群组研究和2期或3期试验。这些药物在日常临床实践中的数据还非常少,特别是在药物的副作用以及与其他药物的相互作用方面,还有它们在特殊人群及不太常见的基因型人群中的使用情况。

据统计,中国的丙肝患者数量在1000-3000万人,而DAA药物(例如索非布韦、达卡他韦等)并没有在中国上市,康安途已经帮助将近500位患者去印度的正规医院获取这些特效新药,治疗效果非常显著,我们正在统计这些患者的服药情况以及治愈率,将整理出第一篇中国人群使用DAA药物治疗的临床研究文章。我们已经在美国临床试验研究网站(clinicaltrials.gov)注册了这一临床项目,编号为。为了更加真实和全面地反应中国人群对于DAA的反应和疗效,希望更多的医生可以加入我们这一研究项目,帮助我们进行患者的跟踪和随访,共同发表这篇临床报道(下附文章的摘要)。相信这个研究项目将对中国丙肝患者今后的临床用药指导带来深远地影响。

你所拥有的特权

1. 共享所有患者的临床研究数据

2. 共同署名即将发表的文章

朱总监电话:17199912074邮箱:zhulan@kangantu.com
康安途海外医疗

上海柯棣健康管理咨询有限公司是由毕业于中国科学院上海生命科学研究院和中国科学院北京基因组研究所的博士团队创立的海外就医服务机构,立志为全球患者提供经济高效的疾病治疗方案,尤其专注于为肝炎患者、肿瘤患者匹配国外已上市的最新药物,提供从疾病咨询,海外就医,用药监控等全方位一站式解决方案。公司致力于整合国外一流的医疗、旅游资源,为国内客户铺设通向海外优质医疗服务资源的无障碍通道,为患者及其家庭带来重生的希望。

团队主要负责人曾经参与过国家“十一五”和“十二五”《艾滋病和病毒性肝炎等重大传染病防治科技重大专项》,还参与过两项丙肝临床研究(clinnicaltrials.gov 注册号: NCT01434212 and NCT01760148),具有丰富的临床研究经验,发表过一系列的文章。

杨晨博士的毕业论文题目是“丙型肝炎病人干扰素疗法的临床耐药的预测方法研究以及治疗效果的机制研究”。 下附中科院上海巴斯德所参与《艾滋病和病毒性肝炎等重大传染病防治科技重大专项》的报道: 中国科学院上海巴斯德研究所

团队成员发表的文章

  • 1Hu Y, Mao K, Zeng Y, Chen S, Tao Z, Yang C, Sun S, et al. Tripartite-motif protein 30 negatively regulates NLRP3 inflammasome activation by modulating reactive oxygen species production. J Immunol 2010;185:7699-7705.
  • 2Wang Y, Yang C, Mao K, Chen S, Meng G, Sun B. Cellular localization of NLRP3 inflammasome. Protein Cell 2013;4:425-431.
  • 3Shi X, Chi X, Pan Y, Gao Y, Li W, Yang C, Zhong J, et al. IL28B is associated with outcomes of chronic HBV infection. Yonsei Med J 2015;56:625-633.
  • 4Yang C, Zhao X, Sun D, Yang L, Chong C, Pan Y, Chi X, et al. Interferon alpha (IFNalpha)-induced TRIM22 interrupts HCV replication by ubiquitinating NS5A. Cell Mol Immunol 2016;13:94-102.
  • 5Dachuan Li, Qing Li, Nong Cheng, Jingyan Song. “Sampling-based real-time motion planning under state uncertainty for autonomous micro aerial vehicles in GPS-denied environments”. Sensors, 2014, 14(11): pp21791-218256.
  • 6Dachuan Li, Qing Li, Liangwen Tang, Sheng Yang, Nong Cheng, Jingyan Song. "Invariant Observer-Based State Estimation for Micro-Aerial Vehicles in GPS-Denied Indoor Environments Using an RGB-D Camera and MEMS Inertial Sensors". Micromachines, 2015, 6(4): pp 487-522
  • 7Qing Li, Dachuan Li, Qinfan Wu, Liangwen Tang, Yan Huo, Yixuan Zhang, Nong Cheng. “Autonomous navigation and environment modeling for MAVs in 3-D enclosed industrial environments,” Computer in Industry, vol.64, no.9: pp 1161-1177, 2013
  • 8Dachuan Li, Qing Li, Nong Cheng, Jingyan Song, “Extended RRT-based path planning for flying robots in complex 3D environments with narrow passages,” in IEEE International Conference on Automation Science and Engineering (CASE), 2012.
  • 9Dachuan Li, Qing Li, Nong Cheng, Qinfan Wu, Jingyan Song, Liangwen Tang, “Combined RGBD-inertial based state estimation for MAV in GPS-denied indoor environments,” in 9th Asian Control Conference, 2013.
  • 10Dachuan Li, Qing Li, Nong Cheng, Qinfan Wu, Jingyan Song, Liangwen Tang, “Invariant observer design of a RGB-D aided inertial system for micro aerial vehicles in GPS-denied environments”, in IEEE International Conference on Systems, Man and Cybernetics (SMC), 2013.
目前正在整理的文章摘要

Abstract: About 130-170 million people, is estimated to be infected with the hepatitis C virus (HCV). Chronic HCV infection is one of the leading causes of liver- related death and in many countries it is the primaryreason for having a liver transplant. The main aim of antiviral treatment is to eradicate the virus. Until a few years ago the only treatment strategy was based on the combination of pegylated interferon and ribavirin (PEG/RBV). However, in genotypes 1 and 4 the rates of viral response did not surpass 50%, reaching up to 80% in the rest. In 2013 and 2014 approval were given for the direct acting antiviral agents (DAA), sovaldi and harvoni, serially, for treatment of HCV patients. These DAA created a new scenario: shorter therapies, less toxicity (free of PEG/RBV), increased rates of SVR (even up to 100%), with pan-genomic properties and excellent tolerance.This has enabled their almost generalised applicability in all patients. Recent years, FDA approved a series of new more effective DAA, However, it should be noted that most of the scientific evidence available is based on expert opinion, case-control series, cohort studies and phase 2 and 3 trials, some with a reduced number of patients and select groups. Few data are currently available about the use of these drugs in daily clinical practice, particularly in relation to the appearance of side effects and interactions with other drugs, or their use in special populations or persons with the less common genotypes. This situation suggests the need for the generalised implementation of registries of patients receiving antiviral therapy. In a clinical study carried out in china, 500 HCV patients received recent DAA treatment. The results indicate that...

Key words: Hepatitis C; Treatment; Direct acting antiviral agents; Chinese Patients; Outcome

朱总监电话:17199912074邮箱:zhulan@kangantu.com
康安途海外医疗
------分隔线----------------------------
关于我们
关于康安
企业文化
招商加盟
发展历程
看病实录
战略布局
康安公告
媒体报道
康安学术
合作伙伴
质检报告
加入我们
联系我们
本周热门文章

微信

微信

扫描二维码
免费咨询医学博士

联系

免费咨询电话:4006 120 152